New antibiotic strategy aims to spare Last-Resort drugs for ICU lung infections
NCT ID NCT04276480
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study looked at whether a common antibiotic, piperacillin-tazobactam, could be used instead of stronger last-resort antibiotics to treat lung infections in ICU patients on ventilators. The patients had resistant bacteria in their gut. The goal was to see if this approach could save lives and reduce the need for stronger drugs. Only 9 patients were enrolled, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTEROBACTERIACEAE INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre hospitalier de la Côte Basque
Bayonne, 64100, France
-
Hopital Pellegrin
Bordeaux, 33000, France
Conditions
Explore the condition pages connected to this study.